Meloxicam affects the inflammatory responses of bovine mammary epithelial cells
- 1 November 2019
- journal article
- research article
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 102 (11) , 10277-10290
Abstract
Nonsteroidal anti-inflammatory drugs are used as supportive therapy with antimicrobial treatments for mastitis in cows to alleviate pain of the inflamed mammary gland. They act mainly by inhibition of cyclooxygenases. Meloxicam (MEL) is a drug designed for cyclooxygenase-2 selectivity, which is upregulated upon inflammation, acting as a key enzyme for the conversion of arachidonic acid to prostaglandins. Although some studies in dairy cows showed positive results in recovery from mastitis when MEL was added to the treatments, direct effects of MEL on the immune system of mastitic cows are unknown. The aim of this study was to investigate effects of MEL on the immune response of bovine mammary epithelial cells (MEC) with or without simultaneous immune stimulation by pathogen-associated molecular patterns of common mastitis pathogens. Mammary epithelial cells from 4 cows were isolated and cultured. To evaluate dose effects of MEL, MEC were challenged with or without 0.2 µg/mL lipopolysaccharide (LPS; serotype O26:B6 from Escherichia coli) with addition of increasing concentrations of MEL (0, 0.25, 0.5, 1.0, 1.5, or 2.0 mg/mL). The addition of MEL prevented the increase of mRNA expression of key inflammatory factors in LPS-challenged MEC in a dose-dependent manner. To investigate the effects of MEL on pathogen-specific immune responses of MEC, treatments included challenges with LPS from E. coli and lipoteichoic acid from Staphylococcus aureus with or without 1.5 mg/mL MEL for 3, 6, and 24 h. Meloxicam prevented the increase of mRNA abundance of key inflammatory mediators in response to LPS and lipoteichoic acid, such as tumor necrosis factor, serum amyloid A, inducible nitric oxide synthase, and the chemokines IL-8 and CXC chemokine ligands 3 and 5. The prostaglandin E2 synthesis in challenged and nonchallenged cells was reduced by MEL within 24 h. Furthermore, MEL reduced the viability and consequently the total RNA yield of the cells. However, mRNA abundance of apoptosis-related enzymes was not affected by any treatment. Meloxicam had clear dose-dependent effects on the immune response of MEC to pathogen-associated molecular patterns of common mastitis pathogens by preventing increased expression of important factors involved in inflammation. This nonsteroidal anti-inflammatory drug also has detrimental effects on cell viability. How these effects would influence the elimination of pathogens from an infected mammary gland during mastitis therapy with meloxicam needs to be further investigated.Keywords
This publication has 31 references indexed in Scilit:
- Neutrophil recruitment and function in health and inflammationNature Reviews Immunology, 2013
- PAMPs and DAMPs: signal 0s that spur autophagy and immunityImmunological Reviews, 2012
- Adipose tissue depots of Holstein cows are immune responsive: Inflammatory gene expression in vitroDomestic Animal Endocrinology, 2010
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- Cryopreserved bovine mammary cells to model epithelial response to infectionVeterinary Immunology and Immunopathology, 2004
- Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanesJournal of Clinical Investigation, 2001
- Do heat shock proteins control the balance of T-cell regulation in inlammatory diseases?Immunology Today, 1998
- Meloxican: Influence on arachidonic acid metabolismBiochemical Pharmacology, 1996
- Meloxican: Influence on arachidonic acid metabolismBiochemical Pharmacology, 1996
- Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes.Journal of Experimental Medicine, 1994